SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is a major talking point following promising clinical data from its Alpha DaRT study, highlighting an 81% disease control rate in advanced pancreatic cancer and the successful treatment of its first U.S. glioblastoma patient. The community is buzzing with anticipation for imminent Japan PMDA approval and reports of Cathie Wood's ARK Invest adding the stock, signaling growing institutional attention for this innovative oncology platform. Investors are keenly watching for further updates from the company's presentation at a key healthcare conference, emphasizing its potential in targeted alpha radiation therapy.

The ticket is $Testicle. EVERY SINGLE ONE OF YOU CAME FROM A $Testicle. $Testicle always bounce.   We have a website on which you can create art or memes. We have a community. We have a raid group. We aim to provide the best testicular care on CT.   We might even have to call on our nefarious leader, Harry Bolz. Alright Chad, SACK TF. Or else you’re a Low T beta male.   If you have questions and or concerns please feel to reach out to a team member on how you can acquire or become a high testosterone male in a sea of betas. I mean how else does one live if not as a High T male?

Testicle

TESTICLE CRYPTO is a top trending meme coin, sparking widespread discussion and a mix of humor and disbelief across the crypto community. Many are questioning its legitimacy, humorously debating its 'nuts' name and the speculative nature of such projects. Its rapid rise highlights a segment of the market drawn to highly speculative and often absurd digital currencies, with some embracing the joke and volatility inherent in these novel assets.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with knife ($CAW) is trending, buoyed by its strong community's belief in it as a legitimate, multichain meme cryptocurrency. Investors are discussing its fully circulated supply, organic growth, and deflationary burn mechanism across Solana, Cronos, and Base. This unique blend of meme culture and robust tokenomics is driving significant conversation.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin (CRO) is trending due to significant strategic partnerships, including High Roller Technologies for prediction markets and Trump Media for digital token distribution and potential ETFs. The community is actively discussing these collaborations, along with a new 21Shares partnership for proposed CRO investment products, as key drivers for broader ecosystem adoption and future growth. Despite mixed sentiment regarding its performance, many anticipate these developments will greatly expand CRO's market presence.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is experiencing significant trending activity following Saudi FDA approvals for its ANKTIVA drug in both bladder and lung cancer, alongside positive updates on its AI-driven manufacturing and strong revenue growth. The investment community is actively discussing the potential for a substantial short squeeze and the company's groundbreaking, chemo-free approach that could mark a paradigm shift in cancer treatment.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors anticipate increased LNG cargo volumes from its rapidly expanding Plaquemines facility, coinciding with a favorable European market seeing cold weather and low gas inventories. The community is buzzing over VG's significant short interest, with many viewing the impact of ongoing legal disputes as overblown given its strong production growth and strategic position as a low-cost LNG exporter.

ETHZilla Corp. is a technology company in the decentralized finance (DeFi) industry, which intends to connect financial institutions, businesses, and organizations worldwide by enabling secure, accessible blockchain transactions through Ethereum Network protocol implementations. It continues to maintain the deployment and development of its biotech and gaming operations. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palm Beach, FL.

ETHZilla Corp

ETHZilla Corporation

ETHZilla is actively discussed after recent announcements including the cancellation of executive stock awards and significant debt retirement, paired with a new stock buyback program. Many bulls anticipate a substantial short squeeze and a value rebound, pointing to improved financials and the company's pivot into real-world asset tokenization, while others express deep frustration over historical underperformance and management's past actions. The broader community is weighing these fundamental shifts against its past as a volatile crypto-related entity.

Hut 8 Corp. operates as a Bitcoin miner that focuses on mining. It provides digital asset mining, hosting, and managed infrastructure operation services. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 is gaining significant attention following its major AI infrastructure partnership with Anthropic and Fluidstack, notably backed by Google, which positions it as a leading player beyond traditional Bitcoin mining. The community is buzzing about this strategic pivot, with many emphasizing the substantial contract potential and how this differentiates Hut 8 from its peers in the rapidly expanding AI data center sector.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network ($ZBCN) is currently trending with heightened community excitement surrounding its recent partnership with World Liberty Finance and the anticipated launch of its Super App. Discussions highlight $ZBCN's robust real-world utility in on-chain payroll and payments, along with its ISO 20022 and MiCA compliance, positioning it for broader adoption. Many within the community view $ZBCN as an undervalued project with significant long-term growth potential, often comparing its early stage to established utility tokens.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is trending due to its strengthened balance sheet from a completed pension reversion, fueling investor excitement around its strategic pivot into pharmaceutical API manufacturing and advanced battery materials. The community anticipates significant government contracts related to national security for domestic pharma supply chains and is discussing a potential revaluation alongside unexpected growth in film sales. Many expect a substantial "Kodak moment" surge as these strategic initiatives gain traction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mind Medicine (MindMed) (NASDAQ:MNMD) Sets New 52-Week High - Still a Buy?

Mind Medicine (MindMed) (NASDAQ:MNMD) Hits New 52-Week High - Time to Buy...

Mind Medicine (MindMed) (NASDAQ:MNMD) Trading Down 3.8% on Insider Selling

Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Down 3.8% After Insider Selling...

Mind Medicine (MindMed) (NASDAQ:MNMD) Insider Sells $148,279.40 in Stock

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Get Free Report) insider Mark Sullivan sold 11,276 shares of the firm's stock in a transaction dated Friday, December 26th. The stock was sold at an...

Mind Medicine (MindMed) (NASDAQ:MNMD) Insider Daniel Karlin Sells 5,600 Shares

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Get Free Report) insider Daniel Karlin sold 5,600 shares of the firm's stock in a transaction on Friday, December 26th. The stock was sold at an average...

Mind Medicine (MindMed) (NASDAQ:MNMD) Insider Mark Sullivan Sells 11,276 Shares

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Get Free Report) insider Mark Sullivan sold 11,276 shares of the company's stock in a transaction dated Friday, December 26th. The shares were sold at an...

Mind Medicine (MindMed) (NASDAQ:MNMD) CEO Sells $339,151.65 in Stock

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Get Free Report) CEO Robert Barrow sold 25,791 shares of the business's stock in a transaction dated Friday, December 26th. The shares were sold at an...

Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Up 3.1% - Should You Buy?

Mind Medicine (MindMed) (NASDAQ:MNMD) Trading Up 3.1% - What's Next...

MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026?

MNMD has surged 101% in six months with MM120 advancing in phase III for GAD and MDD. Pivotal readouts are slated for 2026.

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Consensus Rating of "Buy" from Analysts

Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Get Free Report) have been assigned an average rating of "Buy" from the twelve ratings firms that are currently covering the firm, MarketBeat...

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Average Rating of "Buy" from Analysts

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Get Free Report) has received a consensus rating of "Buy" from the twelve analysts that are presently covering the stock, MarketBeat.com reports. One...

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

MNMD
Mind Medicine Inc - Ordinary Shares (Sub Voting)

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MNMD News

MNMDMind Medicine Inc - Ordinary Shares (Sub Voting)